
Keywords: لاکتات دهیدروژناز (LDH); Eculizumab; Soliris; terminal complement inhibitor; atypical hemolytic uremic syndrome (aHUS); thrombotic microangiopathy (TMA); kidney disease; platelet count; hemoglobin; lactate dehydrogenase (LDH); renal function; hematologic normalization; TMA respon